Could you elaborate on the role/services provided by Indegene to physicians in Wuhan at the time of the coronavirus outbreak?

Dr Saurabh Jain: Indegene is supporting some institutes and professors associated with institutes in Wuhan with data collation, analysis and deploying its medical writers develop manuscripts for each therapy tried on patients of COVID-19, for publishing in global medical journals.

Did that help inform/assess treatment protocols?

Jain: Yes, all published data is helping in the treatment protocol. We are also working on systematic literature review of early stage evidence treatment options and the quality of evidence guiding the therapeutic management of COVID-19.

What kind of broad findings emerged?

Jain: In our recent paper, we have done a systematic literature review of early-stage evidence treatment options hydroxychloroquine, remdesivir, lopinavir, azithromycin, tocilizumab, convalescent plasma and hyperimmune globulin. Early-stage evidence available does not convincingly support in favor of or against a particular therapeutic regimen. This is mainly due to heterogeneity with respect to the patients, pathogen variants and the endpoints.

Is Indegene providing any other services in China with a view to assisting policymakers in arriving at informed disease management decisions?

Jain: Currently, our services are limited to working with individual doctors and hospitals in data collation, analysis and deploying medical writers to develop manuscripts.

Commercial Models Shifting As Pharma Mulls Digital-First Launches

More from Business

More from Scrip